The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

A new approach using lipid nanoparticles to deliver genetic material is showing promise in tackling two major challenges in ...

Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...

Researchers have built an AI-powered pathology tool designed to predict whether small cell lung cancer patients will respond ...

Screening individuals for lung cancer with low-dose CT on a nonrisk basis is associated with a marked reduction in lung cancer mortality and better overall survival, reveals Chinese data.

ORR 35.8% overall, 37.5% in second-/third-line, and 47.1% in light/nonsmokers, with median DOR not reached in key subsets. Exploratory efficacy suggested durable benefit in later lines, including ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...

The response was even stronger when STING activation was paired with DLL3-targeted CAR-NK cell therapy, suggesting that priming the tumor’s vasculature may help engineered NK cells get to the cancer ...